Related Experiment Video

Updated: Jul 8, 2026

Fertility Sparing Procedure using Carbon Dioxide Fiber Laser Vaporization of Ovarian Endometrioma
06:24

Fertility Sparing Procedure using Carbon Dioxide Fiber Laser Vaporization of Ovarian Endometrioma

Published on: July 6, 2022

Ovarian ablation as a non-surgical treatment for breast cancer

John R Benson1

  • 1Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK. John.benson@addenbrookes.nhs.uk

The Lancet. Oncology
|January 8, 2008
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Thermal Ablation for the Treatment of Abdominal Tumors
07:16

Thermal Ablation for the Treatment of Abdominal Tumors

Published on: March 7, 2011

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models
13:43

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models

Published on: April 1, 2022

Related Experiment Videos

Last Updated: Jul 8, 2026

Fertility Sparing Procedure using Carbon Dioxide Fiber Laser Vaporization of Ovarian Endometrioma
06:24

Fertility Sparing Procedure using Carbon Dioxide Fiber Laser Vaporization of Ovarian Endometrioma

Published on: July 6, 2022

Thermal Ablation for the Treatment of Abdominal Tumors
07:16

Thermal Ablation for the Treatment of Abdominal Tumors

Published on: March 7, 2011

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models
13:43

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models

Published on: April 1, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

Breast-Conserving Surgery Versus Mastectomy After Neoadjuvant Therapy: A Survival Analysis.

Annals of surgical oncology·2026

Evaluation of patient experience from participation in the randomized INFLUENCE trial on fluorescence-guided sentinel node surgery.

Surgery·2026

Highlights of the San Antonio breast cancer symposium 2025 (Part 2).

Future oncology (London, England)·2026

Highlights of the San Antonio Breast Cancer Symposium 2025 (Part 1).

Future oncology (London, England)·2026

Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial.

Nature cancer·2026

Non-surgical ablation for breast cancer: an emerging therapeutic option.

The Lancet. Oncology·2024

Global health expenditures on cancer control: a cross-sectional analysis.

The Lancet. Oncology·2026

Long-term exposure to wildfire-related PM2·5 and overall survival of older patients with lung cancer: a retrospective, registry-based cohort study.

The Lancet. Oncology·2026

Burden of cancer in Africa, 1990-2023: a systematic analysis from the Global Burden of Disease Study 2023.

The Lancet. Oncology·2026

Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial.

The Lancet. Oncology·2026

Development and external validation of a new prognostic model for metastatic clear cell renal cell carcinoma: a preregistered analysis using data from randomised clinical trials in the checkpoint inhibitor era.

The Lancet. Oncology·2026

Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial.

The Lancet. Oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us